Target Organs and Levels of Evidence for TR-508
Toxicology and Carcinogenesis Studies of Riddelliine (CASRN 23246-96-0) in F344/N Rats and B6C3F1 Mice (Gavage Studies)
Chemical (Study Title) CASRN |
Peer Review Date | Route/Exposure Levels | Study Laboratory |
---|---|---|---|
Riddelliine 23246-96-0 |
10/18/2001 | Gavage MR: 0 OR 1.0 MG/KG; 50/DOSE FR: 0, 0.01, 0.033, 0.1, 0.33, OR 1.0 MG/KG; 62/DOSE MM: 0, 0.1, 0.3, 1.0, OR 3.0 MG/KG; 50/DOSE FM: 0 OR 3.0 MG/KG; 50/DOSE |
Southern Research Institute |
Levels of Evidence
Male Rats: Clear Evidence
Type | Organ/Tissue (Lesion) |
---|---|
Neoplastic Lesions |
|
Non-Neoplastic Lesions |
|
Female Rats: Clear Evidence
Type | Organ/Tissue (Lesion) |
---|---|
Neoplastic Lesions |
|
Non-Neoplastic Lesions |
|
Male Mice: Clear Evidence
Type | Organ/Tissue (Lesion) |
---|---|
Neoplastic Lesions |
|
Non-Neoplastic Lesions |
|
Other Considerations |
|
Female Mice: Clear Evidence
Type | Organ/Tissue (Lesion) |
---|---|
Neoplastic Lesions |
|
Non-Neoplastic Lesions |
|
Other Considerations |
|